Warby Parker Inc Dossier - Source-backed chat

Warby Parker Inc

WRBYNYSE

SectorHealth Care

IndustryMedical Instruments & Supplies

Beta (adjusted)1.62

Intrinsic Value $17.18median of 5 methods · middle span $10-$23based on filings through 30 Jun 2026

Market Price $27.78Price as of 30 Sep 2026

OvervaluedIntrinsic value is 38% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $3.4B

Enterprise Value $3.1B

Shares Outstanding 125.1M diluted

Moat Rating None

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Warby Parker continues to successfully transition from a digitally native e-commerce disruptor into a vertically integrated, omnichannel vision care platform. The company is driving solid top-line growth and expanding its average revenue per customer by scaling its physical store footprint, expanding eye exam services, and leveraging insurance partnerships. However, near-term headwinds—including a sharp deceleration in active customer growth (slowing to 4.8% in Q1 2026), gross margin compression from tariffs and fixed-cost deleverage, and execution risks surrounding its upcoming fall 2026 AI intelligent eyewear launch—suggest that the stock is currently fairly valued. A Hold rating is recommended as the market digests these margin pressures and monitors the execution of its retail and technology initiatives.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets13 analysts · as of 18 Aug 2026

Low · most bearish analyst$24.00

Mean target$30.46

High · most bullish analyst$35.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$24.0015%

The bear case is triggered by further deceleration in active customer growth due to e-commerce headwinds and saturation in core urban demographics. High stock-based compensation continues to dilute shareholders, while persistent tariff costs, wage inflation for optometrists, and high capital expenditures for store openings prevent meaningful free cash flow generation. Furthermore, the AI intelligent eyewear launch fails to gain traction, leading to inventory write-downs.

Base CaseCentral scenario

$30.4660%

Matches the consensus mean

The base case assumes Warby Parker achieves its reaffirmed FY 2026 guidance of $959 million to $976 million in net revenue (10% to 12% growth) and Adjusted EBITDA of $117 million to $119 million. Active customer growth remains stable but modest in the mid-single digits, while average revenue per customer continues to grow through premium lens upgrades and eye exam adoption. Gross margins remain pressured in the near term by tariffs and retail infrastructure investments, keeping GAAP profitability near breakeven.

Bull CaseUpside scenario

$35.0025%

The bull case is driven by a highly successful launch of the new AI-powered intelligent eyewear in fall 2026, which accelerates active customer acquisition and establishes a high-margin recurring revenue stream. Additionally, rapid expansion of the physical store footprint toward the 900+ target, combined with higher-than-expected insurance penetration and progressive lens mix, drives significant operating leverage and gross margin expansion back toward historical mid-50% levels.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong customer economics with Average Revenue per Customer up 6.9% year-over-year to $331, driven by premium lens enhancements and eye exam adoption.
Substantial retail runway with 337 current stores representing only a fraction of the company's estimated long-term potential of 900+ locations.
Strategic expansion into the massive $70 billion U.S. eyewear market through managed vision care partnerships and upstream eye exam services.

Key Investment Risks

Decelerating active customer growth, which slowed to 4.8% in Q1 2026 compared to 8.7% in the prior-year period, highlighting e-commerce channel challenges.
Gross margin pressure from tariff-related headwinds on glasses, logistics inflation, and fixed-cost deleverage from doctor headcount and occupancy.
Execution and adoption risks associated with entering the complex consumer electronics space with the upcoming fall 2026 AI intelligent eyewear launch.

Thesis Invalidation Triggers

Active customer growth turning negative on a trailing 12-month basis.
Adjusted EBITDA margin expanding by less than 50 basis points in FY 2026, failing to meet the guided 130 basis point expansion.
Severe supply chain disruptions or product recalls associated with the new intelligent eyewear line.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.